Singapore, May 13 -- Singapore's Health Sciences Authority (HSA) and China's National Medical Products Administration (NMPA) have signed a Memorandum of Understanding (MoU) to renew their commitment in health products regulatory collaboration, so as to support faster access to new and innovative health products for patients and healthcare systems in both countries.

The renewed MoU expands the scope of regulatory cooperation into new emerging areas such as cell, tissue and gene therapy products, and strengthens collaboration to explore building facilitative regulatory pathways, pilot innovative schemes, capacity building and staff exchanges.

Published by HT Digital Content Services with permission from BioSpectrum Asia....